It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2019

Evotec and GARDP announce new partnership to discover novel antibiotics
Nerina Coppini, 19 March 2019

Collaboration explores opportunities to set up antibiotic discovery and development platform and establish a joint pipeline of novel antibiotic assets Discovery efforts will focus on World Health Organisation (“WHO”) priority pathogens

2017

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter
Nerina Coppini, 23 May 2017

Our recent collaboration with Massachusetts General Hospital (MGH) on the identification and validation of novel targets in Gram-negative bacteria is covered in the Spring edition of OneNucleus Newsletter. Read the full article on page 8 with our expert, Antonio Felici.

Why We Need a Culture of International Collaboration to Fight Antibiotic Resistance
Nerina Coppini, 19 April 2017

Read the article on antimicrobial resistance from our very own Antonio Felici, which was published in Bioscience Technology this month. Read full article from Bioscience Technology online site

Pharma's Almanac on Aptuit's Collaboration with Bioversys
Nerina Coppini, 6 April 2017

Nice coverage in Pharma's Almanac of Aptuit's collaboration with Bioversys. Aptuit in Bacteria Resistance Collaboration Drug development firm Aptuit has begun a joint collaboration with the Swiss biotech Bioversys that is aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. The partners hope...

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens
Nerina Coppini, 7 March 2017

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard